Laparoscopic Radical Prostatectomy After Previous Transurethral Resection of the Prostate in Clinical T1a and T1b Prostate Cancer: A Matched-Pair Analysis
Affiliations
Purpose: To analyze and compare surgical, oncological and functional outcomes of laparoscopic radical prostatectomy (LRP) in patients with and without previous transurethral resection of the prostate (TURP).
Materials And Methods: In total, 785 men underwent LRP at our institution from January 2002 to December 2012. TURP had been performed previously in 35 of these patients (TURP group). A matched-pair analysis identified 35 additional men without previous TURP who exhibited equivalent clinicopathological characteristics to serve as a control group. Perioperative complications and surgical, functional, and oncological outcomes were compared between the two groups.
Results: The groups were similar in age, body mass index, serum prostate-specific antigen level, and pre- and post-operative Gleason scores. Patients in the TURP group had greater blood loss (231 vs. 139 mL), longer operative times (262 vs. 213 min), a greater probability of transfusion (8.6% vs. 0%), and a higher rate of complications (37.1% vs. 11.4%) compared with the control group. The positive surgical margin rate was higher in the TURP group, but this difference was not statistically significant (P = .179). The continence rates at one year after surgery were similar, but a lower continence rate was identified in the TURP group (42.9% vs. 68.6%) at 3 months. Biochemical recurrence developed in 17.1% and 11.4% of the patients in the TURP and control groups, respectively, after a mean follow-up of 57.6 months.
Conclusion: LRP is feasible but challenging after TURP. LRP entails longer operating times, greater blood loss, higher complication rates and worse short-term continence outcomes. However, the radical nature of this cancer surgery is not compromised.
Wang Y, Zheng X, Mao Q, Xie L Arch Med Sci. 2024; 20(1):133-137.
PMID: 38414460 PMC: 10895939. DOI: 10.5114/aoms.2020.94681.
Creta M, Manfredi C, Arcaniolo D, Spirito L, Kaplan S, Woo H Prostate Cancer Prostatic Dis. 2023; 27(3):367-384.
PMID: 37244971 DOI: 10.1038/s41391-023-00678-y.
Liu Y, Qin J, Li K, Wen Z, Huang J, Jiang Y J Robot Surg. 2023; 17(4):1271-1285.
PMID: 36929480 DOI: 10.1007/s11701-023-01555-5.
The Management of Patients Diagnosed with Incidental Prostate Cancer: Narrative Review.
Abedi A, Ghiasy S, Fallah-Karkan M, Rahavian A, Allameh F Res Rep Urol. 2020; 12:105-109.
PMID: 32215268 PMC: 7083625. DOI: 10.2147/RRU.S245669.
Li H, Zhao C, Liu P, Hu J, Yi Z, Chen J Transl Androl Urol. 2020; 8(6):712-727.
PMID: 32038968 PMC: 6987598. DOI: 10.21037/tau.2019.11.13.